Datapoint: Lilly Scores First-Ever Alopecia Areata Nod

With this week’s FDA approval, Eli Lilly and Incyte’s Olumiant is first-ever treatment for alopecia areata, an autoimmune disease that causes a severe form of hair loss. The JAK inhibitor was first approved in 2018 as a rheumatoid arthritis therapy. For the treatment of rheumatoid arthritis, Olumiant holds covered or better status for 61% of all insured lives. Just 11% of insured lives have preferred access to Olumiant.

SOURCE: MMIT Analytics, as of 6/15/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 1

Datapoint: BMS Asks Supreme Court to Rehear CAR-T Dispute

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 30

Datapoint: New Startup Insurer to Expand to Six More States

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 29

Datapoint: FDA Approves Lilly’s Interchangeable Insulin

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today